These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 20197548

  • 1. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG.
    Blood; 2010 Apr 29; 115(17):3589-97. PubMed ID: 20197548
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.
    PLoS One; 2006 Dec 20; 1(1):e18. PubMed ID: 17183644
    [Abstract] [Full Text] [Related]

  • 4. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
    Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.
    Blood; 2006 Jun 01; 107(11):4274-81. PubMed ID: 16478879
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
    Wiśniewska-Chudy E, Szylberg Ł, Dworacki G, Mizera-Nyczak E, Marszałek A.
    Oncol Rep; 2017 Apr 01; 37(4):2295-2307. PubMed ID: 28260027
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
    Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR.
    N Engl J Med; 2007 Feb 01; 356(5):459-68. PubMed ID: 17267906
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe H, Katayose KS, Kubuki Y, Kusumoto K, Hasuike S, Tahara Y, Nagata K, Matsuda T, Ohshima K, Harada M, Shimoda K.
    Leukemia; 2008 Jan 01; 22(1):87-95. PubMed ID: 18033315
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S.
    Oncogene; 2011 Feb 24; 30(8):990-1001. PubMed ID: 21042281
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.
    Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V.
    Exp Hematol; 2009 Oct 24; 37(10):1194-200. PubMed ID: 19615425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.